Skip to main content Accessibility help
×
Home

Is there an MCI reversion to cognitively normal? Analysis of Alzheimer's disease biomarkers profiles

  • Moon Ho Park (a1) and Changsu Han (a2)

Abstract

Background:

We investigated the characteristics of Alzheimer's disease (AD) biomarkers for mild cognitive impairment (MCI) reversion to cognitively normal (CN).

Methods:

Of a total of 1,233 participants from the ADNI database, 42 participants with MCI reversion to CN (MCIr), 778 with MCI, and 413 CN were obtained. We evaluated demographics, clinical outcomes, medication use, MCI type, and AD biomarkers, including genetic, cerebrospinal fluid, imaging, and neuropsychological data.

Results:

This study showed that the differences between MCIr and CN were only age, Mini-Mental State Examination, and Clinical Dementia Rating – Sum of Boxes, but the differences between MCIr and MCI were not only clinical outcomes but also AD biomarkers, including genetic, cerebrospinal fluid, imaging, and neuropsychological data. Overall, MCIr may be similar to CN and not MCI in clinical characteristics.

Conclusions:

With assessment of MCI reversion to CN, the possibility of false-positive errors should be considered. With the assistance of AD biomarkers, MCI can be evaluated more accurately than the conventional criteria.

Copyright

Corresponding author

Correspondence should be addressed to: Dr. Moon Ho Park, MD, PhD, Department of Neurology, Korea University Ansan Hospital, 516, Gojan-dong, Danwon-gu, Ansan-si, Gyeonggi-do, South Korea. Phone: +82-31-412-5150; Fax: +82-31-412-5154. Email: parkmuno@yahoo.co.kr.

References

Hide All
ADNI. (2013a). ADNI prcedures, protocols and grants. In Alzheimer's Disease Neuroimaging Initiative. Available at: http://www.adni-info.org/Scientists/ADNIStudyProcedures.aspx; last accessed 17 November 2013.
ADNI. (2013b). Download study data. In Alzheimer’ Disease Neuroimaging Initiative. Available at: https://ida.loni.usc.edu/pages/access/studyData.jsp; last accessed 17 November 2013.
Albert, M. S. et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 7, 270279. doi:10.1016/j.jalz.2011.03.008.
Busse, A., Hensel, A., Guhne, U., Angermeyer, M. C. and Riedel-Heller, S. G. (2006). Mild cognitive impairment: long-term course of four clinical subtypes. Neurology, 67, 21762185. doi:10.1212/01.wnl.0000249117.23318.e1.
de Jager, C. A. and Budge, M. M. (2005). Stability and predictability of the classification of mild cognitive impairment as assessed by episodic memory test performance over time. Neurocase, 11, 7279. doi:10.1080/13554790490896820.
Edmonds, E. C. et al. (2014). Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. Alzheimer's and Dementia. Epublished ahead of print, doi:10.1016/j.jalz.2014.03.005.
Fisk, J. D., Merry, H. R. and Rockwood, K. (2003). Variations in case definition affect prevalence but not outcomes of mild cognitive impairment. Neurology, 61, 11791184.
Gallassi, R. et al. (2010). Are subjective cognitive complaints a risk factor for dementia? Neurological Science, 31, 327336. doi:10.1007/s10072-010-0224-6.
Ganguli, M., Dodge, H. H., Shen, C. and DeKosky, S. T. (2004). Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology, 63, 115121.
Ganguli, M. et al. (2011). Outcomes of mild cognitive impairment by definition: a population study. Archives of Neurology, 68, 761767. doi:10.1001/archneurol.2011.101.
Han, J. W. et al. (2012). Predictive validity and diagnostic stability of mild cognitive impairment subtypes. Alzheimer's and Dementia, 8, 553559. doi:10.1016/j.jalz.2011.08.007.
Jack, C. R. Jr., et al. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurology, 9, 119128. doi:10.1016/S1474-4422(09)70299-6.
Klekociuk, S. Z., Summers, J. J., Vickers, J. C. and Summers, M. J. (2014). Reducing false positive diagnoses in mild cognitive impairment: the importance of comprehensive neuropsychological assessment. European Journal of Neurololgy, 21, 1330e1383. doi:10.1111/ene.12488.
Koepsell, T. D. and Monsell, S. E. (2012). Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis. Neurology, 79, 15911598. doi:10.1212/WNL.0b013e31826e26b7.
Larrieu, S. et al. (2002). Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology, 59, 15941599.
Lezak, M. D., Howieson, D. B., Bigler, E. D. and Tranel, D. (2012). Neuropsychological Assessment. Oxford, UK: Oxford University Press.
Lopez, O. L. et al. (2012). Incidence of mild cognitive impairment in the Pittsburgh Cardiovascular Health Study – Cognition Study. Neurology, 79, 15991606. doi:10.1212/WNL.0b013e31826e25f0.
Mitchell, A. J. and Shiri-Feshki, M. (2009). Rate of progression of mild cognitive impairment to dementia–meta-analysis of 41 robust inception cohort studies. Acta Psychiatrica Scandinavica, 119, 252265. doi:10.1111/j.1600-0447.2008.01326.x.
Mormino, E. C. et al. (2009). Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain, 132, 13101323. doi:10.1093/brain/awn320.
Nordlund, A., Rolstad, S., Klang, O., Edman, A., Hansen, S. and Wallin, A. (2010). Two-year outcome of MCI subtypes and aetiologies in the Goteborg MCI study. Journal of Neurology, Neurosurgery, and Psychiatry, 81, 541546. doi:10.1136/jnnp.2008.171066.
Olazaran, J. et al. (2011). Mild cognitive impairment and dementia in primary care: the value of medical history. Family Practice, 28, 385392. doi:10.1093/fampra/cmr005.
Petersen, R. C. (2011). Clinical practice. Mild cognitive impairment. New England Journal of Medicine, 364, 22272234. doi:10.1056/NEJMcp0910237.
Petersen, R. C. et al. (2010). Alzheimer's Disease neuroimaging initiative (ADNI): clinical characterization. Neurology, 74, 201209. doi:10.1212/WNL.0b013e3181cb3e25.
Reitz, C., Brayne, C. and Mayeux, R. (2011). Epidemiology of Alzheimer's disease. Nature Reviews. Neurology, 7, 137152. doi:10.1038/nrneurol.2011.2.
Roberts, R. O. et al. (2014). Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal. Neurology, 82, 317325. doi:10.1212/WNL.0000000000000055.
Rosen, C., Hansson, O., Blennow, K. and Zetterberg, H. (2013). Fluid biomarkers in Alzheimer's disease – current concepts. Molecular Neurodegeneration, 8, 20. doi:10.1186/1750-1326-8-20.
Shaw, L. M. et al. (2009). Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Annals of Neurology, 65, 403413. doi:10.1002/ana.21610.
Sperling, R. A. et al. (2011). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia, 7, 280292. doi:10.1016/j.jalz.2011.03.003.
Tyas, S. L. et al. (2007). Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study. American Journal of Epidemiology, 165, 12311238. doi:10.1093/aje/kwm085.
Zonderman, A. B. and Dore, G. A. (2014). Risk of dementia after fluctuating mild cognitive impairment: when the yo-yoing stops. Neurology, 82, 290291. doi:10.1212/WNL.0000000000000065.

Keywords

Is there an MCI reversion to cognitively normal? Analysis of Alzheimer's disease biomarkers profiles

  • Moon Ho Park (a1) and Changsu Han (a2)

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed